Delcath Systems Inc. (DCTH)

Delcath's HEPZATO shows rapid sales growth and high pricing, but its efficacy is only moderately better than alternatives and not curative. The addressable market is small, treatment is complex, and f...

Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.

The average of price targets set by Wall Street analysts indicates a potential upside of 48.7% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, th...

Delcath Systems (DCTH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancer...

Delcath's commercial execution post-HEPZATO launch has driven impressive revenue growth, positive cash flow, and a shift from speculative to established biotech. Q1 earnings beat expectations with 530...

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha...

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...

Delcath Systems, Inc. (NASDAQ:DCTH ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard...

Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.43 per share a year ago.